Insider Trading Alert - EAT, VRX, CMA, RAI And GD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 28, 2014, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $440.99 to $7,539,344.56.

Highlighted Stocks Traded by Insiders:

Brinker International (EAT) - FREE Research Report

Thomson Roger F who is EVP, CAO, General Counsel at Brinker International sold 14,452 shares at $50.12 on Jan. 28, 2014. Following this transaction, the EVP, CAO, General Counsel owned 93,723 shares meaning that the stake was reduced by 13.36% with the 14,452-share transaction.

The shares most recently traded at $48.08, down $2.04, or 4.25% since the insider transaction. Historical insider transactions for Brinker International go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 5,863
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 32,492
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 103,020

The average volume for Brinker International has been 948,600 shares per day over the past 30 days. Brinker International has a market cap of $3.3 billion and is part of the services sector and leisure industry. Shares are up 5.24% year-to-date as of the close of trading on Tuesday.

Brinker International, Inc. owns, develops, operates, and franchises full-service casual dining restaurants under the Chili's Grill & Bar and Maggiano's Little Italy brands primarily in the United States. As of September 25, 2013, it owned, operated, or franchised 1,596 restaurants. The stock currently has a dividend yield of 1.97%. The company has a P/E ratio of 20.8. Currently there are 7 analysts that rate Brinker International a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EAT - FREE

TheStreet Quant Ratings rates Brinker International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, reasonable valuation levels and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Brinker International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Kornwasser Laizer who is EVP, Company Group Chairman at Valeant Pharmaceuticals International bought 2,536 shares at $132.15 on Jan. 28, 2014. Following this transaction, the EVP, Company Group Chairman owned 28,390 shares meaning that the stake was reduced by 9.81% with the 2,536-share transaction.

The shares most recently traded at $132.08, down $0.07, or 0.05% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 184,247
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 189,247
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 248,779
  • 24-Week # shares sold: 19,000

The average volume for Valeant Pharmaceuticals International has been 1.2 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $43.6 billion and is part of the health care sector and drugs industry. Shares are up 13.12% year-to-date as of the close of trading on Tuesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Comerica (CMA) - FREE Research Report

Turner Reginald M JR who is Director at Comerica bought 200 shares at $47.62 on Jan. 28, 2014. Following this transaction, the Director owned 3,200 shares meaning that the stake was reduced by 6.67% with the 200-share transaction.

The shares most recently traded at $46.40, down $1.22, or 2.63% since the insider transaction. Historical insider transactions for Comerica go as follows:

  • 24-Week # shares sold: 7,314

The average volume for Comerica has been 1.3 million shares per day over the past 30 days. Comerica has a market cap of $8.5 billion and is part of the financial sector and banking industry. Shares are down 1.6% year-to-date as of the close of trading on Tuesday.

Comerica Incorporated, through its subsidiaries, provides financial products and services primarily in Texas, Arizona, California, Florida, and Michigan. The company operates in three segments: Business Bank, Retail Bank, and Wealth Management. The stock currently has a dividend yield of 1.63%. The company has a P/E ratio of 15.5. Currently there are 3 analysts that rate Comerica a buy, 8 analysts rate it a sell, and 15 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMA - FREE

TheStreet Quant Ratings rates Comerica as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins, solid stock price performance, reasonable valuation levels and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Comerica Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Reynolds American (RAI) - FREE Research Report

Brown & Williamson Holdings, Inc. who is 10% Owner at Reynolds American sold 153,676 shares at $49.06 on Jan. 28, 2014. Following this transaction, the 10% Owner owned 225.8 million shares meaning that the stake was reduced by 0.07% with the 153,676-share transaction.

The shares most recently traded at $48.46, down $0.60, or 1.24% since the insider transaction. Historical insider transactions for Reynolds American go as follows:

  • 4-Week # shares sold: 311,196
  • 12-Week # shares sold: 954,204
  • 24-Week # shares sold: 2.2 million

The average volume for Reynolds American has been 2.0 million shares per day over the past 30 days. Reynolds American has a market cap of $26.5 billion and is part of the consumer goods sector and tobacco industry. Shares are down 1.26% year-to-date as of the close of trading on Tuesday.

Reynolds American Inc., through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. The company operates through RJR Tobacco, American Snuff, and Santa Fe segments. The stock currently has a dividend yield of 5.14%. The company has a P/E ratio of 17.2. Currently there are 2 analysts that rate Reynolds American a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RAI - FREE

TheStreet Quant Ratings rates Reynolds American as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Reynolds American Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

General Dynamics (GD) - FREE Research Report

Heebner David K who is Executive Vice President at General Dynamics sold 6,538 shares at $99.75 on Jan. 28, 2014. Following this transaction, the Executive Vice President owned 140,379 shares meaning that the stake was reduced by 4.45% with the 6,538-share transaction.

The shares most recently traded at $99.23, down $0.52, or 0.52% since the insider transaction. Historical insider transactions for General Dynamics go as follows:

  • 4-Week # shares sold: 11,825
  • 12-Week # shares sold: 15,825
  • 24-Week # shares sold: 40,825

The average volume for General Dynamics has been 1.7 million shares per day over the past 30 days. General Dynamics has a market cap of $35.2 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 5.18% year-to-date as of the close of trading on Tuesday.

General Dynamics Corporation, an aerospace and defense company, provides business aviation; combat vehicles, weapons systems, and munitions; military and commercial shipbuilding; and communications and information technology products and services worldwide. The stock currently has a dividend yield of 2.24%. The company has a P/E ratio of 14.2. Currently there are 14 analysts that rate General Dynamics a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GD - FREE

TheStreet Quant Ratings rates General Dynamics as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, attractive valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full General Dynamics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Samsung Posts Record Q1 But Adds Cautious Voice To Smartphone Demand Forecasts

Samsung Posts Record Q1 But Adds Cautious Voice To Smartphone Demand Forecasts

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer